GlassScriptPhysician profile
Ashley Adale James
NPI 1093290512
$2,509.88
in general payments reported to CMS, 2019-2025
20 companies · $823 in 2025
The $823 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.95 · 2023: $678 · 2024: $926 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $606.26 | 2022-2025 | Auvelity |
| Abbvie INC. | $570.04 | 2023-2025 | |
| Lilly USA, LLC | $219.43 | 2022-2025 | Mounjaro, Zepbound |
| Corcept Therapeutics | $198.41 | 2024-2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.63 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $138.56 | 2024-2025 | Fanapt, Hetlioz |
| Bayer Healthcare Pharmaceuticals INC. | $105.12 | 2024-2025 | |
| Alkermes, INC. | $79.05 | 2022-2024 | Lybalvi |
| Novo Nordisk INC | $77.59 | 2023-2024 | Wegovy, Rybelsus |
| Amgen INC. | $65.60 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $49.75 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $46.97 | 2024-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $46.75 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $31.71 | 2024 | |
| Lundbeck LLC | $30.78 | 2023-2024 | Rexulti, Abilify Maintena |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.27 | 2024 | Farxiga |
| Astellas Pharma US INC | $15.68 | 2025 | Veozah |
| Exact Sciences Corporation | $14.40 | 2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $13.47 | 2025 | Jornay Pm |
| Corium, LLC | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.